Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.58), $0.15 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.68 million.

As of December 31, 2021, cash, cash equivalents, and marketable securities were $218.2 million, as compared to $112.9 million as of December 31, 2020. Based on current plans, the company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2024.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.